Aveo Pharmaceuticals (AVEO)
ASCO presentation: Full presentation of results from the phase III study of tivozanib in kidney cancer.What we already know: Top-line results from the kidney cancer study were announced in early January with tivozanib demonstrating a progression-free survival of 11.9 months compared to 9.1 months for Nexavar. In a subset of treatment-naive patients, tivozanib PFS was 12.7 months. Key questions: Nexavar performed better than expected in the study, which narrowed the benefit shown by tivozanib and caused some investors to question the tivozanib's true efficacy. Aveo asserts tivozanib's safety data (to be fully disclosed at ASCO) demonstrates superiority over Nexavar.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV